{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:40:42Z","timestamp":1743036042040,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":25,"publisher":"Springer New York","isbn-type":[{"type":"print","value":"9781493940097"},{"type":"electronic","value":"9781493940110"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-1-4939-4011-0_4","type":"book-chapter","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:40:51Z","timestamp":1472604051000},"page":"37-45","source":"Crossref","is-referenced-by-count":0,"title":["Immunological Analyses of Leukemia Stem Cells"],"prefix":"10.1007","author":[{"given":"Kazuhito","family":"Naka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Takihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"4_CR1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5:172\u2013183","journal-title":"Nat Rev Cancer"},{"key":"4_CR2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.molmed.2007.09.003","volume":"13","author":"DS Krause","year":"2007","unstructured":"Krause DS, Van Etten RA (2007) Right on target: eradicating leukemic stem cells. Trends Mol Med 13:470\u2013481","journal-title":"Trends Mol Med"},{"key":"4_CR3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc2368","volume":"8","author":"M Savona","year":"2008","unstructured":"Savona M, Talpaz M (2008) Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 8:341\u2013350","journal-title":"Nat Rev Cancer"},{"key":"4_CR4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O\u2019Hare","year":"2012","unstructured":"O\u2019Hare T, Zabriskie MS, Eiring AM, Deininger MW (2012) Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 12:513\u2013526","journal-title":"Nat Rev Cancer"},{"key":"4_CR5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/asheducation-2013.1.189","volume":"2013","author":"W Ahmed","year":"2013","unstructured":"Ahmed W, Van Etten RA (2013) Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program 2013:189\u2013200","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"4_CR6","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","volume":"101","author":"R Bhatia","year":"2013","unstructured":"Bhatia R et al (2013) Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101:4701\u20134707","journal-title":"Blood"},{"key":"4_CR7","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"key":"4_CR8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054\u20131061","journal-title":"Leukemia"},{"key":"4_CR9","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1586\/ehm.10.61","volume":"3","author":"FJ Giles","year":"2010","unstructured":"Giles FJ et al (2010) Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Rev Hematol 3:665\u2013673","journal-title":"Expert Rev Hematol"},{"key":"4_CR10","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270","journal-title":"N Engl J Med"},{"key":"4_CR11","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"24","author":"DM Ross","year":"2010","unstructured":"Ross DM et al (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24:1719\u20131724","journal-title":"Leukemia"},{"key":"4_CR12","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","volume":"117","author":"AR Ibrahim","year":"2011","unstructured":"Ibrahim AR et al (2011) Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117:3733\u20133736","journal-title":"Blood"},{"key":"4_CR13","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/bph.12183","volume":"169","author":"A Sinclair","year":"2013","unstructured":"Sinclair A, Latif AL, Holyoake TL (2013) Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol 169:1693\u20131707","journal-title":"Br J Pharmacol"},{"key":"4_CR14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s13238-013-2115-0","volume":"4","author":"H Zhang","year":"2013","unstructured":"Zhang H, Li S (2013) Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells. Protein Cell 4:186\u2013196","journal-title":"Protein Cell"},{"key":"4_CR15","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","volume":"463","author":"K Naka","year":"2010","unstructured":"Naka K et al (2010) TGF-\u03b2-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 463:676\u2013680","journal-title":"Nature"},{"key":"4_CR16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/71691","volume":"24","author":"CS Huettner","year":"2000","unstructured":"Huettner CS, Zhang P, Van Etten RA, Tenen DG (2000) Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 24:57\u201360","journal-title":"Nat Genet"},{"key":"4_CR17","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","volume":"105","author":"S Koschmieder","year":"2005","unstructured":"Koschmieder S et al (2005) Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 105:324\u2013334","journal-title":"Blood"},{"key":"4_CR18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","volume":"20","author":"D Reynaud","year":"2011","unstructured":"Reynaud D et al (2011) IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 20:661\u2013673","journal-title":"Cancer Cell"},{"key":"4_CR19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","volume":"21","author":"L Li","year":"2012","unstructured":"Li L et al (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21:266\u2013281","journal-title":"Cancer Cell"},{"key":"4_CR20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","volume":"21","author":"B Zhang","year":"2012","unstructured":"Zhang B et al (2012) Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 21:577\u2013592","journal-title":"Cancer Cell"},{"key":"4_CR21","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cell.2015.04.054","volume":"161","author":"CR Mantel","year":"2015","unstructured":"Mantel CR et al (2015) Enhancing hematopoietic stem cell transplantation efficacy by mitigating oxygen shock. Cell 161:1553\u20131565","journal-title":"Cell"},{"key":"4_CR22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","volume":"30","author":"DM Gwinn","year":"2008","unstructured":"Gwinn DM et al (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30:214\u2013226","journal-title":"Mol Cell"},{"key":"4_CR23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","volume":"12","author":"R Zoncu","year":"2011","unstructured":"Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12:21\u201335","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4_CR24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrm3522","volume":"14","author":"JL Jewell","year":"2013","unstructured":"Jewell JL, Russell RC, Guan KL (2013) Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol 14:133\u2013139","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4_CR25","doi-asserted-by":"publisher","first-page":"8039","DOI":"10.1038\/ncomms9039","volume":"6","author":"K Naka","year":"2015","unstructured":"Naka K\u00a0et al (2015) Dipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells. Nat Commun 6:8039. doi: 10.1038\/ncomms9039","journal-title":"Nat Commun"}],"container-title":["Methods in Molecular Biology","Chronic Myeloid Leukemia"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-4011-0_4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T22:50:36Z","timestamp":1568328636000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-4011-0_4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9781493940097","9781493940110"],"references-count":25,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-4011-0_4","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2016]]}}}